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Human induced pluripotent stem cells (hiPSCs) have core properties of unlimited self-renewal and diﬀerentiation potential and
have emerged as exciting cell sources for applications in regenerative medicine, drug discovery, understanding of development,
and disease etiology. Key among numerous criteria to assess pluripotency includes the in vivo teratoma assay that has been widely
proposedasastandardfunctionalassaytodemonstratethepluripotencyofhiPSCs.Yet,thelackofreliabilityacrossmethodologies,
lack of deﬁnitive clinical signiﬁcance, and associated expenses bring into question use of the teratoma assay as the “gold standard”
for determining pluripotency. We propose use of the in vitro embryoid body (EB) assay as an important alternative to the teratoma
assay. This paper summarizes the methodologies for creating EBs from hiPSCs and the subsequent analyses to assess pluripotency
andproposesitsuseasacost-eﬀective,controlled,andreproducibleapproachthatcaneasilybeadoptedtodeterminepluripotency
of generated hiPSCs.
1.Introduction
Human induced pluripotent stem cells (hiPSCs) are devel-
oping as exciting cell sources for applications in regenera-
tive medicine [1] and drug discovery, primarily based on
their extensive similarities to their human embryonic stem
cell counterparts and shared properties of self-renewal and
multilineage diﬀerentiation capabilities. The strategy of in-
ducing pluripotency by activating the pluripotent network
has proven to be successful in the reprogramming of somatic
cells back to an embryonic-like state [2, 3]. However, there
is a critical need to assess the pluripotent capabilities of the
hiPSCs on a line-by-line basis once reprogramming has
occurred to demonstrate this diﬀerentiation potential.
Multiple criteria have been proposed to evaluate the
pluripotentstateofgeneratedhiPSCs[4–6].Keyamongthese
criteria includes routine morphological analysis of cells for
the presence of high nuclear-cytoplasmic ratio, cell surface
and gene expression of pluripotent markers, demonstration
of diﬀerentiation capabilities into derivatives from the three
developmentalgermlayers(ectoderm,endoderm,andmeso-
derm), and specialized functional outcomes to demonstrate
developmental potency. The functional assays developed
thus far include in vitro diﬀerentiation, teratoma formation,
chimera development, germline transmission, and tetraploid
complementation [7] .T h em o s ts t r i n g e n tt e s tt os c r e e nf o r
pluripotency is the ability to demonstrate germline compe-
tency after chimera development, a test that can easily be
conducted for mouse iPSCs. For hiPSCs, where testing for
germline transmission and tetraploid complementation is
not possible, teratoma formation of hiPSCs injected into im-
munocompromised mice and subsequent analysis of tissue
formation has been widely used as an important methodol-
ogy to investigate the developmental ability of the generated
hiPSCs.2 Stem Cells International
2. The Teratoma Assay for
Pluripotency Assessment
Teratomasaresolid,deﬁnedtumors,oftengerm-linederived,
composed of the highly organized diﬀerentiated cells and
tissues containing representatives of the three developmental
germ layers that can also be generated artiﬁcially by trans-
planting pluripotent stem cells (hESCs or hiPSCs) into
immunodeﬁcient mice [8]. The histopathology of teratomas
is remarkable in that they can serve as an important tool
to observe early morphogenesis into organized tissues. The
number of cells transplanted into the immunodeﬁcient
animal model in order to generate the fully diﬀerentiated
teratoma in vivo can range anywhere between a hundred to
a million cells or more [9]. As part of this methodology, the
generated hiPSCs are usually transplanted at the following
sites: intramuscular, subcutaneous, under the testis capsule,
or under the kidney capsule in an immune deﬁcient mouse.
After a period of at least three weeks, the mature teratomas
are excised out of the animal to be assessed for the presence
of the cells derived from the three germ layers. The teratoma
assay has been proposed to be the most stringent means to
assess pluripotency of hiPSCs [10] but is not as rigid as the
tetraploid complementation and germline transmission that
can be conducted with mouse iPSCs [11]. In addition, the
high costs associated with the assay, use of dozens or hun-
dreds of animals, lack of a deﬁnitive clinical or biological
relevance of the ability to form teratomas to the speciﬁc cell
types subsequently derived from the hiPSCs, and the nonsys-
tematic way this assay has been employed bring into ques-
tion the use of the teratoma assay as the “gold standard”
[4, 6, 8, 11].
Recent reports have highlighted the need to standardize
the protocol to generate and examine the teratomas induced
in the immunodeﬁcient mouse models, if they are to be used
as the gold standard for assessing pluripotency in generated
hiPSCs [8, 10]. Studies have shown that some of the hiPSC
lineshavenotbeensuccessfulinformingallthreegermlayers
in the teratomas but have been successful in deriving certain
cell types that may have clinical signiﬁcance [12]. Other re-
searchers have also found that partially reprogrammed
hiPSCs can form teratomas even if they do not meet other
criteriaforpluripotency,leadingmanytoquestiontheoverall
signiﬁcance of the teratoma assay [6]. Generation of system-
atic protocols for teratoma generation and analysis that can
be adopted across diﬀerent labs also remains a challenge [8].
3.Embryoid Bodies asaMeans to
Assess Pluripotency of hiPSCs
An important alternative method to the teratoma assay is
an in vitro approach involving the generation of embryoid
bodies (EBs) from hiPSCs. EBs are three-dimensional aggre-
gates of cells that are an amalgam of the three developmental
germlayers[7].Inthisapproach,theundiﬀerentiatedhiPSCs
areplacedinsuspension,whichpromotesstochasticdiﬀeren-
tiation into cells of all three germ layers. Formation of EBs
is a routine approach used in the diﬀerentiation of the
hiPSCs into diﬀerent cell lineages [13]. One of the major
advantages of this approach is that it is performed in vitro
with standard tissue culture methods and materials, thus
avoiding the regulatory issues and extensive expenses associ-
ated with maintaining immune-deﬁcient mice. The EBs can
be easily grown in a suspension culture in a petri dish in the
laboratoryandcanbescaledupwithoutmuchdiﬃcultyonce
the appropriate conditions for scale-up are established [14].
Unlike the teratoma assay in which hiPSCs that have passed
all other pluripotency tests yet fail to form teratomas for
unknownreasons[12],hiPSCsreadilyformEBsbyanumber
of methods providing the ability to demonstrate trilineage
diﬀerentiation and analysis in a more controlled, repro-
ducible manner. The numerous approaches that have been
developedtogenerateEBsalongwiththeestablishedanalyses
used for their pluripotent assessment are summarized in the
following sections.
4. Methodologies for the Formation of
hiPSC Embryoid Bodies
T h e r eh a v eb e e ns e v e r a lm e t h o d sd e v e l o p e dt oc r e a t ee m b ry -
oid bodies for a variety of purposes, from the generation of
speciﬁc tissue types to stochastic in vitro germ layer diﬀer-
entiation, to illustrate potency of candidate pluripotent stem
cell lines [13, 15–17] (summarized in Table 1). For speciﬁc
tissue lineages, EBs have been shown to be beneﬁcial in the
initiation of diﬀerentiation and to enhance the diﬀerentia-
tion towards certain lineages [18]s u c ha sh e m a t o p o i e t i c[ 15,
19],neural[20,21],andcardiactissues[22–25].Methodsfor
developing EBs diﬀer in their ability to form aggregates of
uniform size and the maintenance of their long-term viabil-
ity. Typically, it is advantageous to control the uniform size
of EBs for the reproducible diﬀerentiation of speciﬁc tissue
types; however, the ability to form EBs of varied size for
extended culture periods facilitates the formation of diverse
tissues representing the three germ layers as a means to
demonstrate diﬀerentiation potential. Both types of tech-
niques can be used for the assessment of pluripotent stem
line (hESC, hiPSC) quality.
4.1. Heterogeneous Methods of Embryoid Body Formation.
Methods for the creation of stochastic EBs are the most
straightforward and useful for the generation of varied germ
layer representatives for subsequent demonstration of plu-
ripotency [16]. Liquid suspension culture (LSC, [15]) is a
common method for creating EBs and depends on the ability
to grow cellular aggregates without attachment to the tissue
culture vessel (Figure 1(a)). Typical tissue culture vessels
for this purpose range from nontissue culture-treated petri-
dishes to specially treated ultra-low attachment surfaces
available through several vendors. These low-attachment tis-
sue culture vessels are typically coated to provide a neutral,
hydrophilic surface to prevent protein adsorption and subse-
quent cell attachment [26]. Hydrogels, such as naturally
occurring agarose, or chemically deﬁned, synthetic materials
such as polyhydroxyethylmethacrylate (pHEMA) have been
used to coat vessel surfaces to prevent the attachment of cellsStem Cells International 3
Table 1: Common techniques to form human embryoid bodies.
Controls
EB size
Need for single cell
suspension
Large-scale bioreactor
production
Need for special
equipment References
Heterogeneous methods
Liquid suspension culture No No No No [15, 16]
Stirred ﬂask culture No No Yes Yes [27]
Rotary cell culture systems (RCCSS) No No Yes Yes [28, 29]
Homogeneous methods
Hanging drop culture Yes Yes No No [13, 30, 31]
Low adhesion U-bottom multiwell plates Yes No No No [14]
Indented solid microsurfaces (AggrewellTM) Yes Yes No Yes [32]
Other methods
Hydrogels (e.g., methylcellulose, agarose, alginate) No Yes No No [15, 33, 34]
(a) (b) (c) (d)
(e) (f) (g)
Figure 1: Schematic representation of methods to form embryoid bodies from pluripotent stem cells includes (a) liquid suspension culture,
(b) stirred ﬂask culture, (c) rotary cell culture systems, (d) hanging drop culture, (e) low adhesion U-bottom multiwall plates, (f) indented
solid microsurfaces, and (g) hydrogel culture systems.
for the purpose of creating suspension cellular aggregates
[26]. Though these surface treatments prevent the cell at-
tachment to the tissue culture vessel resulting in aggregation,
initial seeding densities need to be optimized in order to
facilitate the cell-cell interactions required to form appropri-
ately sized EBs. Seeding densities that are too low result in
poor aggregation thus resulting in poorly established EB cul-
tures. Thus, typical seeding densities are kept quite high dur-
ing the initial aggregation (minimum of 106 cells per 2mL
media in a 50mm plate [16] or 6-well plate well). In the case
of pluripotent hESC and hiPSC cultures, it is often desirable
to facilitate the initial aggregation step by transferring iso-
lated sections of colonies to low attachment vessels, since
theseculturestendtobenegativelyeﬀectedbybeinginsingle
cell suspension resulting in poor viability by apoptosis [35].
Once formed, suspension EBs cultures are typically cultured
in the low attachment vessel for an extended period of time,
typically from 28 to 35 days with fresh medium exchange
every2-3days,thoughlongerculturetimesmaybedesirable.
Medium conditions have been demonstrated to have an im-
portant inﬂuence on the viability and germ layer diﬀerentia-
tion of the suspended EBs. For instance, studies have shown
that culture of EBs in a physiological glucose concentration
(5.5mM as opposed to 25mM high glucose formulations
typical of hESC and hiPSC expansion medium) in the
presence of basic ﬁbroblast growth factor (bFGF) prolonged
the viability and increased the complexity of tissues in the
EBs showing that representatives of all three germ layers in
cultures could be maintained up to 105 days [36].
Though static suspension cultures of EBs are the most
widely used due to their simplicity and the minimal cost of
low-attachment treated standard vessels (dishes and multi-
wellplates), recentadvances in bioreactorsuspension culture
have demonstrated usefulness of these techniques to opti-
mize, standardize, and scale up the formation of EBs [17, 28,
29]. Unlike static suspension cultures, these systems require
specialized culture equipment such as stirred ﬂasks or the
more recent Rotating Cell Culture Systems (RCCSs), devel-
opedbyNASA,eithertheSlowTurningLateralVessel(STLV)
or the larger capacity High Aspect Rotating Vessel (HARV)
[37–39]. Typical stirred ﬂask methodologies involve seeding
hESC or hiPSC suspensions in a specialized ﬂask utilizing
a magnetic stirring bar to continually rotate the culture in
order to facilitate aggregation of the cells into sustained cel-
lular aggregates and provide better gas exchange than static
systems [27]( Figure 1(b)). This method has been used to
derive EBs and is amendable to scale up for larger yields [27].
Unlike these stirred ﬂask suspension systems which allow for4 Stem Cells International
the EBs to be agitated over culture time allowing for greater
gas exchange, less hypoxia, and less agglomeration than the
static suspension system [27], the RCCS systems greatly re-
duce shear forces, present in the stirred ﬂask systems, which
can greatly damage the EBs [40, 41]. Often termed “micro-
gravity” cell culture, RCCS systems allow for the continuous
horizontal rotation resulting in very low shear stress on the
cells, active membrane-based gas diﬀusion to prevent hypo-
xia and to equally distribute both oxygen and expiration
waste gas, and can partially control EB size by regulating ro-
tation speed and initial seeding densities (Figure 1(c)). Using
these RCCS systems, the STLV in particular with its high
membrane surface area to medium volume compared to the
larger HARV, it has been demonstrated that EBs cultured
in this fashion demonstrated higher viability, more complex
tissue diﬀerentiation, and, in a speciﬁc example of neural
induction, enhancement of neural progenitor diﬀerentiation
[42].
4.2. Homogenous Methods of Embryoid Body Formation. As
opposed to the heterogeneous methods of EB formation
that result in representatives of the three germ layers in a
stochastic culture, it is frequently the case that more con-
trolled EB formation methods for increased reproducibility
and size control can facilitate the diﬀerentiation towards spe-
ciﬁc tissue types. In particular, control of EB size has been
demonstrated to inﬂuence viability, proliferation, and diﬀer-
entiation potential [26] to cardiomyocytes [22, 25, 30, 43],
endothelialtissue[43],aswellasinstructhematopoiesis[19].
Several methods have been developed in order to form
EBs of deﬁned size. These methods share in their method-
ology ways to segregate a deﬁned number of cells in order
to allow them to aggregate before being collected for further
culture. The hanging drop method utilizes 20–25μLd r o p s
containing a deﬁned number of cells (typically 1000–10000)
in single cell suspension [13, 30, 31] .T h ed r o p sa r ep l a c e d
onto the underside of a ﬂipped 100mm tissue culture plate
lid, typically a maximum of 96 drops if using a multichannel
pipette to place the drops (Figure 1(d)). Once placed, the lid
is carefully ﬂipped allowing the drops to remain attached
to the lid and the lid is placed over a buﬀer-ﬁlled plate to
prevent evaporation of the hanging drops. This technique is
limited in the upper size limit of the initial cell aggregate due
to the limited volume of the hanging drop required to allow
ﬂuidtensiontoadherethedroptothelid(20to25μL).Initial
formationofthecellularaggregatestypicallytakes1to2days,
after which the EBs are individually collected manually and
placed in low-adhesion plates for further culture and matu-
ration. A variation on the hanging drop using round bottom
ultra-low attachment-treated multiwall plates has also been
developed which allows for the derivation of larger EBs than
the hanging drop method, in that larger amounts of cells can
be placed into each well (i.e., 100–200μL of cell suspension
per well in 96-well round-bottom plates) (Figure 1(e))[ 14].
More recently, using a silicon wafer-based microfabrication
technologycontaininghundredsorthousandsofmicrometer
sized wells per cm2 adhered to the well bottoms of a standard
multiwallplate,studieshavedemonstratedtheabilitytoform
large numbers of uniform and synchronized human EBs of
deﬁned size [32] in a commercially available format (Aggre-
WellTM, Stem Cell Technologies) (Figure 1(f)). Though these
techniquesallowforthecontrolledaggregationofhESCsand
hiPSCs, both require the formation of single cell suspensions
exposing the cells to low viability and poor EB formation
and, in the case of the plate based systems, centrifugation in
order to force settle the cells into the bottom of the wells. It
is common, therefore, that protective agents, such as the ad-
dition of Rho-associated kinase (ROCK) inhibitor, Y-27632,
are required for these methods [35].
4.3. Other Embryoid Body Formation Methodologies. The EB
formation methods discussed previously represent the most
commonly used for the purpose of assessing hESC and
hiPSC pluripotency in vitro. Other more speciﬁc approaches
exist for niche applications such as encapsulation techniques
utilizing hydrogels such as methylcellulose [15, 33]o rh y a l u -
ronic acid (HA) [34]. These techniques allow for the entrap-
ment of single cells in suspension and subsequent growth of
cellular aggregates (Figure 1(g)). These techniques have been
mostly utilized for more speciﬁc goals than pluripotency
assessment such as when cell clusters derived from single-cell
clones are desirable. These techniques often suﬀer from very
low yields [15] due to the intrinsic instability of prolonged
singlecellcultureofthepluripotentstemcellsaswellascom-
plicating the isolation of EBs from the hydrogel for subse-
quent downstream analyses.
5. Analysis of GermLayer Formation in
hiPSC-DerivedEmbryoid Bodies
In order to assess the pluripotency of hiPSCs by the in vitro
method of deriving EBs, it is imperative to have deﬁnitive
downstream assays that demonstrate the ability to form rep-
resentatives of the three developmental germ layers, thus
demonstrating their increased diﬀerentiation potency upon
reprogramming. There are several methods to show this that
range from less stringent (showing expression of germ layer-
speciﬁc genes) to the more stringent and deﬁnitive demon-
stration of tissue-similar structures (histology and immuno-
histochemistry) that resemble early embryonic development
along with the concomitant expression of markers. This
section will brieﬂy review the typical requirements for such
analyses.
5.1. Expression of Germ Layer-Speciﬁc Genes. Perhaps the
least stringent test of pluripotency in EBs is the demonstra-
tion of germ layer-speciﬁc gene expression by biochemical
means. The reason for the lower stringency is that this only
represents the ability to detect such gene expression without
knowledge of higher-order structural or temporal expression
within organized structures which can be discerned by more
extensive histological and immunohistochemical examina-
tion (see the following). However, it is clear that the input
cells, often ﬁbroblasts in the case of their derivation toward
hiPSCs, do not express these genes and can be used as an in-
dicator of acquired tissue speciﬁc expression [61]( i . e . ,n e u -
ral-speciﬁc genes being expressed). Gene expression analysisStem Cells International 5
Table 2: Typical markers for the analysis of human embryoid bodies.
Marker name Alternate name Marker type Suitable marker for
gene expression
Suitable marker
for IHC Reference
Pluripotency
Oct4 (POU5F1) Octamer-binding
transcription factor 4 Transcription factor Yes Yes [44]
Nanog n/a Transcription factor Yes Yes [45]
REX-1 Zinc ﬁnger protein 42
homolog (ZFP42) Transcription factor Yes Yes [2]
SOX-2 SRY (sex determining
region Y)-box 2 Transcription factor Yes Yes [46]
SSEA-3 Stage-speciﬁc embryonic
antigen 3 (SSEA-3) Surface antigen No Yes [47]
SSEA-4 Stage-speciﬁc embryonic
antigen 3 (SSEA-4) Surface antigen No Yes [47]
Tra-I-60 n/a Surface antigen No Yes [48]
Tra-I-81 n/a Surface antigen No Yes [48]
Ectoderm
GFAP Glial ﬁbrillary acidic
protein
Glial intermediate
ﬁlament Yes Yes [49]
Nestin n/a Intermediate ﬁlament Yes Yes [49]
Pax-6 Paired box gene 6 Transcription factor Yes Yes [50]
Sox-1 Sex determining region
Y-box 1 Transcription factor Yes Yes [51]
Endoderm
AFP Alpha-fetoprotein Plasma Protein Yes No [52]
Amylase Alpha-amylase Metabolic Enzyme Yes Yes [53]
FOXA2 Hepatocyte nuclear
factor 3-beta (HNF-3B) Transcription Factor Yes Yes [54]
PDX1
Pancreatic and duodenal
homeobox 1, insulin
promoter factor 1
Transcription factor Yes Yes [55]
GATA4 GATA binding protein 4 Transcription factor Yes Yes [56]
Mesoderm
Brachyury n/a Transcription factor Yes Yes [57]
CD34 Cluster of diﬀerentiation
molecule 34 Surface antigen No Yes [58]
FLT1 Vascular endothelial
growth factor receptor 1 Surface receptor Yes Yes [59]
RUNX1 AML1, Runt-related
transcription factor 1 Transcription factor Yes Yes [60]
is also often used to demonstrate the lack of pluripotency
genes upon EB diﬀerentiation, thus demonstrating the
completeness of diﬀerentiation. This is of particular concern
with hiPSCs, in order to demonstrate that the factors used
to reprogram in the case of integrating retroviruses are in
fact silenced [62]. There are several pluripotent and germ
layer-speciﬁc markers used for the purpose of ascertaining
diﬀerentiation within EBs (Table 2).
5.2. Histological Analysis of Embryoid Bodies. Though gene
expression analysis can be used to identify the presence of
germ layer-speciﬁc markers and the concomitant lose of
pluripotent markers, a more deﬁnitive assessment of tissue
diﬀerentiation is based on the histological evaluation of sec-
tioned EBs followed by assessment of tissue organization,
cellular morphology, and localized protein expression [16,
28, 29, 36, 63]. Typically, EBs are ﬁrst pelleted and embedded
(i.e., low-melting point agarose) in order to concentrate the
EBs for subsequent paraﬃn embedding and sectioning for
mounting on microscope slides [63]. These slide-mounted
sections are then stained with hematoxylin-eosin (H&E)
in order to enhance contrast between the tissues and cells
(Figure 2). Using these techniques, various tissues can be
commonly recognized such as neural rosettes (ectoderm-
Figures 2(a), 2(d), 2(g),a n d2(j)), connective tissue (meso-
derm-Figures 2(b), 2(e), 2(h),a n d2(k)), and putative
endoderm (Figures 2(c), 2(f), 2(i),a n d2(l)). Though this
technique is commonly used for both EBs and teratomas to
determine the presence of germ layer representatives once
their histomorphologies are identiﬁed, the assessment can6 Stem Cells International
(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
(j) (k) (l)
Figure 2: Histological evidence of germ layer diﬀerentiation in embryoid bodies generated from human pluripotent stem cells cultured
by diﬀerent methods to illustrate equivalence of culture techniques [63]. Shown are images of hematoxylin and eosin-stained histologic
sections of EBs from hESCs propagated directly on mouse embryonic ﬁbroblast (MEF) feeder layer (top row, a–c) or hESCs propagated in
indirect coculture with MEFs (second row, d–f), hiPSCs propagated on MEFs (third row, g–i), or hiPSCs propagated in indirect coculture
with MEFs (bottom row, j–l). Equivalent trilineage potential is demonstrated by presence of ectodermal (neuroepithelial) (a, d, g, and j);
mesodermal (ﬁbrous connective) (b, e, h, and k), and endodermal (intestinal) (c, f, i, and l) diﬀerentiation in these EBs. Arrows point to the
corresponding tissue in each ﬁgure. Magniﬁcation is 400x total (10x ocular, 40x objective). Each scale bar represents 50μmi nl e n g t h .
(a) (b) (c)
Figure 3: Immunohistochemical analysis of embryoid body sections conﬁrming neuroepithelial tissue in adjacent sections, hematoxylin,
and eosin-stained neural rosettes in hiPSCs-derived EBs (a), antinestin immunoﬂuorescent staining (b), green-nestin, blue-nuclei stain, and
anti-Sox2 immunoﬂuorescent staining (c), red-Sox2, blue-nuclei stain. Magniﬁcation is 400x total (10x ocular, 40x objective). Each scale bar
represents 50μmi nl e n g t h .Stem Cells International 7
be subjective and may require further immunohistochemical
analysis in order to conﬁrm the interpretation using speciﬁc
antibodies(Table 2 andFigure 3)insectionsadjacenttoH&E
stained sections. This is particularly true of putative endo-
derm, which is less prevalent and typically less mature in
embryoid bodies than the more straightforward identiﬁca-
tion of neural and connective tissues.
6. Conclusions
Although hiPSCs reprogrammed from human somatic cells
have been well documented as a source of pluripotent stem
cells with numerous shared similarities with hESCs, the in-
creasing establishment of many new hiPSC lines requires the
useofmultipleassaysandextensiveresourcestodemonstrate
their pluripotency on a line-by-line basis. Key among these
is assays to demonstrate the potency towards formation of
the three developmental germ layers and subsequent deriva-
tion of speciﬁc diﬀerentiated cell types in order to demon-
strate their therapeutic potential. Recently, there has been
enormous debate in the international stem cell community
on the feasibility and use of the in vivo teratoma assay to
demonstrate the pluripotency of derived hiPSCs [4, 6, 8–
11]. Our paper proposes the embryoid body (EB) assay as
a useful in vitro, cost-eﬀective alternate to demonstrate the
diﬀerentiation potential of derived hiPSCs. Methods for the
generation of EBs and subsequent biochemical and histo-
logical analysis have gone through steady and tremendous
improvements which permits its use across diﬀerent labora-
tories. Further reﬁnement and automation of the proposed
methodologies providesopportunities forapplicationsofthe
EB assay as a gold standard for assessing pluripotency of
generated hiPSCs.
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